Research graph
References from Preclinical Herb–Drug Pharmacokinetic Interaction of Panax ginseng Extract and Selegiline in Freely Moving Rats. Local targets link to admitted publications; unresolved targets remain external evidence.
Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease
10.1007/s00702-018-1853-9 · 2018 · External reference
MAO-inhibitors in Parkinson’s Disease
10.5607/en.2011.20.1.1 · 2011 · External reference
Pharmacoresistant convulsions and visual hallucinations around two weeks after selegiline overdose: a case report
10.1055/s-0031-1284429 · 2011 · External reference
Selegiline: a reappraisal of its role in Parkinson disease
10.1097/wnf.0b013e318255838b · 2012 · External reference
The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson’s disease
10.1517/17425255.2013.781152 · 2013 · External reference
Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report
10.2147/ndt.s49261 · 2013 · External reference
A double-blind, placebo-controlled study of selegiline transdermal system in depressed adolescents
10.1089/cap.2013.0138 · 2014 · External reference
Selegiline induces a wake promoting effect in rats which is related to formation of its active metabolites
10.1016/j.pbb.2016.10.003 · 2016 · External reference
Unresolved reference
External reference
Hepatoprotective activity of ginsenosides from Panax ginseng adventitious roots against carbon tetrachloride treated hepatic injury in rats
10.1016/j.jep.2014.10.047 · 2014 · External reference
Enzyme-modified Panax ginseng inhibits UVB-induced skin aging through the regulation of procollagen type I and MMP-1 expression
10.1039/c3fo60418g · 2014 · External reference
Usage of plant food supplements across six European countries: findings from the PlantLIBRA consumer survey
10.1371/journal.pone.0092265 · 2014 · External reference
Potential neuroprotective activity of Ginseng in Parkinson’s disease: a review
10.1007/s11481-014-9569-6 · 2015 · External reference
Pharmacokinetic Drug Interactions with Panax ginseng
10.1007/s13318-016-0387-5 · 2017 · External reference
Electrochemical generation of selegiline metabolites coupled to mass spectrometry
10.1016/j.chroma.2015.02.049 · 2015 · External reference
Distribution of N-methyl-(14)C-labeled selegiline in the rat
10.1016/j.jpba.2015.03.022 · 2015 · External reference
In Vitro Confirmation of Selegiline N-Oxidation by Flavin-Containing Monooxygenase in Rat Microsome Using LC-ESI MS
10.1248/bpb.27.1572 · 2004 · External reference
Urinary excretion of selegiline N-oxide, a new indicator for selegiline administration in man
10.1080/00498250210144857 · 2002 · External reference
Metabolism of Selegiline Hydrochloride, a Selective Monoamine B-type Inhibitor, in Human Liver Microsomes
10.2133/dmpk.17.199 · 2002 · External reference
Effect of Red Ginseng on cytochrome P450 and P-glycoprotein activities in healthy volunteers
10.1016/j.jgr.2015.11.005 · 2016 · External reference
In vitro formation of selegiline-N-oxide as a metabolite of selegiline in human, hamster, mouse, rat, guinea-pig, rabbit and dog
10.1007/bf03190594 · 2004 · External reference
Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients
10.1016/j.ctrv.2012.12.008 · 2013 · External reference
Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction
10.1517/17425255.2.6.875 · 2006 · External reference
Repeated administration of Sailuotong, a fixed combination of Panax ginseng, Ginkgo biloba, and Crocus sativus extracts for vascular dementia, alters CYP450 activities in rats
10.1016/j.phymed.2017.02.007 · 2018 · External reference
